Cullinan Oncology, Inc. (NASDAQ: CGEM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ:AMEX Investor Relations:
investorshub.advfn.com/consolidated-gems-inc-cgem-26232
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
CGEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEM alerts
High impacting Cullinan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGEM
News
- Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitGlobeNewswire
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024GlobeNewswire
- Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target lowered by analysts at HC Wainwright from $29.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsGlobeNewswire
CGEM
Earnings
- 5/15/24 - Beat
CGEM
Sec Filings
- 5/23/24 - Form 8-K
- 5/23/24 - Form 4
- 5/16/24 - Form 4
- CGEM's page on the SEC website